Rahayu Endang Sutriswati, Mariyatun Mariyatun, Putri Manurung Nancy Eka, Hasan Pratama Nur, Therdtatha Phatthanaphong, Mishima Riko, Komalasari Husnita, Mahfuzah Nurul Ain, Pamungkaningtyas Fathyah Hanum, Yoga Wahyu Krisna, Nurfiana Dina Aulia, Liwan Stefanie Yolanda, Juffrie Mohammad, Nugroho Agung Endro, Utami Tyas
Department of Food and Agricultural Technology, Faculty of Agricultural Technology, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 774 Motooka, Nishi-ku, Fukuoka, Japan.
World J Gastroenterol. 2021 Jan 7;27(1):107-128. doi: 10.3748/wjg.v27.i1.107.
Shifting on lifestyle, diet, and physical activity contributed on increasing number of obese people around the world. Multiple factors influence the development of obesity. Some research suggested that gut microbiota (GM) plays an important role in nutrient absorption and energy regulation of individuals, thus affecting their nutritional status. Report of Indonesia Basic Health Research showed that the prevalence of obesity in every province tended to increase. Although the root cause of obesity is excessive calorie intake compared with expenditure, the differences in gut microbial ecology between healthy and obese humans may affect energy homeostasis. GM affect body weight, especially obesity. Probiotics that are consumed while alive and able to colonize in the intestine are expected to increase the population of good bacteria, especially and Lactobacilli, and suppress pathogens such as and . The strain of Dad-13 has been demonstrated to survive and colonize in the gastrointestinal tract of healthy Indonesian adults who consume fermented milk containing Dad-13. The consumption of probiotic Dad-13 powder decreased and non- coliform bacteria in school-aged children in Indonesia. is a dominant bacterium in the average Indonesian's GM. For this reason, this bacterium is probably a more suitable probiotic for Indonesians.
To determine the effect of the consumption of indigenous probiotic Dad-13 powder in overweight adults in Yogyakarta (Indonesia).
Sixty overweight volunteers with a body mass index (BMI) equal to or greater than 25 consume indigenous probiotic powder Dad-13 (2 × 10 CFU/gram/sachet) for 90 d. The study was a randomized, double-blind, placebo-controlled study. The volunteers filled in a diary on a daily basis, which consisted of questions on study product intake (only during ingestion period), other food intake, number of bowel movements, fecal quality (consistency and color), any medications received, and any symptom of discomfort, such as diarrhea, constipation, vomiting, gassing, sensation of illness, Fecal samples and the subjects' diaries were collected on the morning of day 10 + 1, which was marked as the end of the baseline period and the start of the ingestion period. During the ingestion period (from day 11 to day 101), several parameters to measure and analyze the results included body weight and height (once a month), the lipid profile, GM analysis using MiSeq, short-chain fatty acid (SCFA) analysis using gas chromatography, and the measurement of fecal pH using a pH meter.
The consumption of indigenous probiotic powder Dad-13 caused the average body weight and BMI of the probiotic group to decrease from 84.54 ± 17.64 kg to 83.14 ± 14.71 kg and 33.10 ± 6.15 kg/m to 32.57 ± 5.01 kg/m, respectively. No significant reduction of body weight and BMI in the placebo group was observed. An analysis of the microbiota showed that the number of , specifically , increased significantly, while that of significantly decreased. No significant change in lipid profile in both groups was found. Also, no significant change in SCFAs (, butyrate, propionate, acetic acid) and pH level was found after the consumption of the probiotic.
No significant differences in pH before and after ingestion were observed in both the probiotic and placebo groups as well as in the lipid profile of both cholesterol and triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the LDL/HDL ratio. In addition, no significant changes in the concentration of SCFAs (, acetic acid, propionate, and butyrate) were found after con-sumption. Interestingly, a significant decrease in body weight and BMI ( < 0.05) was determined in the treatment group. An analysis of GM shows that Dad-13 caused the population to decrease and the population (especially ) to increase.
生活方式、饮食和身体活动的改变导致全球肥胖人数增加。多种因素影响肥胖的发展。一些研究表明,肠道微生物群(GM)在个体的营养吸收和能量调节中起重要作用,从而影响其营养状况。印度尼西亚基础健康研究报告显示,每个省份的肥胖患病率都有上升趋势。虽然肥胖的根本原因是热量摄入超过消耗,但健康人和肥胖者肠道微生物生态的差异可能会影响能量平衡。GM会影响体重,尤其是肥胖。食用活的且能够在肠道定植的益生菌有望增加有益菌的数量,尤其是双歧杆菌和乳酸杆菌,并抑制诸如大肠杆菌和梭状芽孢杆菌等病原体。Dad-13菌株已被证明能在食用含Dad-13发酵乳的健康印度尼西亚成年人的胃肠道中存活并定植。食用益生菌Dad-13粉末可减少印度尼西亚学龄儿童中的大肠杆菌和非大肠杆菌。大肠杆菌是印度尼西亚人GM中的优势菌。因此,这种细菌可能更适合印度尼西亚人作为益生菌。
确定食用本地益生菌Dad-13粉末对印度尼西亚日惹超重成年人的影响。
60名体重指数(BMI)等于或大于25的超重志愿者食用本地益生菌粉末Dad-13(2×10CFU/克/袋),持续90天。该研究为随机、双盲、安慰剂对照研究。志愿者每天填写日记,内容包括关于研究产品摄入(仅在摄入期)、其他食物摄入、排便次数、粪便质量(稠度和颜色)、所服用的任何药物以及任何不适症状,如腹泻、便秘、呕吐、肠胃胀气、患病感觉等问题。在第10 + 1天上午收集粪便样本和受试者日记,这一天被标记为基线期结束和摄入期开始。在摄入期(从第11天到第101天),用于测量和分析结果的几个参数包括体重和身高(每月一次)、血脂谱、使用MiSeq进行GM分析、使用气相色谱法进行短链脂肪酸(SCFA)分析以及使用pH计测量粪便pH值。
食用本地益生菌粉末Dad-13导致益生菌组的平均体重和BMI分别从84.54±17.64千克降至83.14±14.71千克,从33.10±6.15千克/米²降至32.57±5.01千克/米²。安慰剂组未观察到体重和BMI有显著下降。微生物群分析表明,大肠杆菌的数量,特别是大肠杆菌的数量显著增加,而梭状芽孢杆菌的数量显著减少。两组的血脂谱均未发现显著变化。此外,食用益生菌后,SCFAs(丁酸、丙酸、乙酸)和pH水平也未发现显著变化。
益生菌组和安慰剂组摄入前后的pH值以及胆固醇、甘油三酯、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和LDL/HDL比值的血脂谱均无显著差异。此外,食用后SCFAs(丁酸、乙酸、丙酸和丁酸)的浓度也未发现显著变化。有趣的是,治疗组的体重和BMI显著下降(P<0.05)。GM分析表明,Dad-13导致大肠杆菌数量减少,双歧杆菌数量(尤其是双歧杆菌)增加。